Insights

Innovative Delivery Platform GenEdit's NanoGalaxy platform offers a proprietary library of polymer nanoparticles tailored for tissue-specific gene delivery, presenting opportunities to collaborate with biotech and pharma companies seeking advanced delivery mechanisms for nucleic acid therapeutics.

Expanding Therapeutic Pipeline With ongoing development of gene-editing therapies for neuromuscular and autoimmune diseases, there is potential to partner with clinical-stage organizations aiming to accelerate their own genetic medicine programs using innovative nanoparticle delivery systems.

Strong Funding & Growth Having secured $26 million in Series A funding and generating revenue between $25 million and $50 million, GenEdit demonstrates financial stability and growth, making it a compelling partner for joint ventures and licensing agreements in the genetic medicine space.

Strategic Partnerships Collaborations with industry leaders like Sarepta Therapeutics and Genentech highlight GenEdit's recognized potential; these relationships open avenues to explore further partnerships with biotech firms seeking to leverage advanced delivery technologies for novel therapies.

Focus on Unmet Needs By targeting diseases with high unmet medical needs through internally developed pipelines and strategic collaborations, GenEdit offers sales opportunities with biotech and pharmaceutical companies looking to enhance their therapeutic options with cutting-edge genetic delivery solutions.

GenEdit Tech Stack

GenEdit uses 8 technology products and services including cdnjs, oEmbed, JSON-LD, and more. Explore GenEdit's tech stack below.

  • cdnjs
    Content Delivery Network
  • oEmbed
    Dev Tools
  • JSON-LD
    Javascript Frameworks
  • Choices
    Javascript Libraries
  • Lightbox
    Javascript Libraries
  • PHP
    Programming Languages
  • Lever
    Recruitment Marketing
  • Google Analytics
    Web Analytics

Media & News

GenEdit's Email Address Formats

GenEdit uses at least 1 format(s):
GenEdit Email FormatsExamplePercentage
FLast@genedit.comJDoe@genedit.com
88%
Last@genedit.comDoe@genedit.com
10%
First@genedit.comJohn@genedit.com
1%
FirstL@genedit.comJohnD@genedit.com
1%

Frequently Asked Questions

Where is GenEdit's headquarters located?

Minus sign iconPlus sign icon
GenEdit's main headquarters is located at 681 Gateway Blvd, Suite 313 South San Francisco, California 94080, US. The company has employees across 1 continents, including North America.

What is GenEdit's official website and social media links?

Minus sign iconPlus sign icon
GenEdit's official website is genedit.com and has social profiles on LinkedInCrunchbase.

What is GenEdit's SIC code NAICS code?

Minus sign iconPlus sign icon
GenEdit's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does GenEdit have currently?

Minus sign iconPlus sign icon
As of October 2025, GenEdit has approximately 57 employees across 1 continents, including North America. Key team members include Co-Founder & Chief Operating Officer: H. M. P.Partner: R. V.Associate Project Manager: K. U.. Explore GenEdit's employee directory with LeadIQ.

What industry does GenEdit belong to?

Minus sign iconPlus sign icon
GenEdit operates in the Biotechnology Research industry.

What technology does GenEdit use?

Minus sign iconPlus sign icon
GenEdit's tech stack includes cdnjsoEmbedJSON-LDChoicesLightboxPHPLeverGoogle Analytics.

What is GenEdit's email format?

Minus sign iconPlus sign icon
GenEdit's email format typically follows the pattern of FLast@genedit.com. Find more GenEdit email formats with LeadIQ.

How much funding has GenEdit raised to date?

Minus sign iconPlus sign icon
As of October 2025, GenEdit has raised $24M in funding. The last funding round occurred on Jan 23, 2024 for $24M.

When was GenEdit founded?

Minus sign iconPlus sign icon
GenEdit was founded in 2016.
GenEdit

GenEdit

Biotechnology ResearchUnited States51-200 Employees

GenEdit is focused on overcoming the major challenge to genetic medicines:  Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible.  

The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease.

We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.

Section iconCompany Overview

Headquarters
681 Gateway Blvd, Suite 313 South San Francisco, California 94080, US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
51-200

Section iconFunding & Financials

  • $24M

    GenEdit has raised a total of $24M of funding over 7 rounds. Their latest funding round was raised on Jan 23, 2024 in the amount of $24M.

  • $25M$50M

    GenEdit's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $24M

    GenEdit has raised a total of $24M of funding over 7 rounds. Their latest funding round was raised on Jan 23, 2024 in the amount of $24M.

  • $25M$50M

    GenEdit's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.